Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Profusa ( (PFSA) ) has provided an update.
On August 6, 2025, Profusa, Inc. announced significant milestones, including its recent public listing on Nasdaq and strategic plans for growth. The company outlined a five-pillar strategy focusing on revenue growth, AI infrastructure, clinical pathways, financial strategies, and scaling operations. Profusa is advancing its Lumee™ platform for tissue oxygen monitoring, targeting a European launch in Q1 2026, and plans to expand into the U.S. market by 2027. The company also aims to commercialize its glucose monitoring platform by mid-2027, supported by a $100 million ELOC facility to ensure financial stability.
More about Profusa
Profusa, based in Berkeley, California, is a commercial stage digital health company focused on developing tissue-integrated sensors for continuous monitoring of biochemistry. The company aims to provide personalized biochemical data for personal and medical use through its injectable biosensors and intelligent data platform.
Average Trading Volume: 7,375,546
Technical Sentiment Signal: Sell
Current Market Cap: $17.36M
Learn more about PFSA stock on TipRanks’ Stock Analysis page.